Peru’s Ex-President Martín Vizcarra Sentenced to 14 Years in Prison for Corruption 
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
Trump Administration to Secure Equity Stake in Pat Gelsinger’s XLight Startup 
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO 
Judge Dismisses Charges Against Comey and Letitia James After Ruling on Prosecutor’s Appointment 
Gold Prices Steady as Markets Await Key U.S. Data and Expected Fed Rate Cut 
European Stocks Rise as Markets Await Key U.S. Inflation Data 
Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout 
Intel Rejects TSMC’s Allegations of Trade-Secret Leaks as Legal Battle Escalates 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
Netflix Nearing Major Deal to Acquire Warner Bros Discovery Assets 
Key Witness Seeks to Block Evidence in Potential Revival of Comey Case 
Singapore Court Allows $2.7 Billion 1MDB Lawsuit Against Standard Chartered to Proceed 
Bolsonaro Detained Over Alleged Escape Risk After Ankle Monitor Tampering 
CDC Shake-Up Sparks Vaccine Policy Clash Between RFK Jr. and Susan Monarez 
Asian Currencies Edge Higher as Markets Look to Fed Rate Cut; Rupee Steadies Near Record Lows 
Europe Confronts Rising Competitive Pressure as China Accelerates Export-Led Growth 
Fifty-seven lawsuits alleging that hair relaxer products sold by L'Oreal USA Inc and two India-based firms cause cancer and other health problems will be consolidated before US District Judge Mary Rowland in Chicago,
The Chicago federal court will streamline discovery efforts and other pretrial issues for the cases, according to the order.
The lawsuits, which have been filed in federal courts across the country, alleged that the companies knew about the dangerous chemicals in their products but marketed and sold them anyway.
The cases name the US subsidiary of L'Oreal SA and subsidiaries of India-based companies Godrej SON Holdings Inc. and Dabur International Ltd.
Representatives for the companies opposed the centralization of the cases.
L'Oreal said it is confident in the safety of its products and that lawsuits against it have no legal merit.
The claims come in response to a National Institutes of Health research that was published in October and revealed that women who used the products frequently had a greater than doubled risk of developing uterine cancer.
The panel's decision, according to Diandra Debrosse Zimmermann of DiCello Levitt, who filed the initial case after the study's publication, "recognized the clear benefits of centralizing the hair relaxer litigation," and she anticipates that many more companies will do the same in the upcoming weeks.
As the goods are often promoted to women of color, Zimmermann expects hundreds of women may end up suing over them.
